Tislelizumab monotherapy in patients with previously untreated early-stage classical Hodgkin lymphoma: a real-world study

被引:0
|
作者
Peng Sun
Hang Yang
Yu Wang
Baitian Zhao
Man Nie
Kangming Huang
Zhiming Li
机构
[1] Sun Yat-Sen University Cancer Center,Department of Medical Oncology
[2] State Key Laboratory of Oncology in South China,Department of Clinical Trials Center
[3] Guangdong Provincial Clinical Research Center for Cancer,undefined
[4] Sun Yat-Sen University Cancer Center,undefined
来源
Annals of Hematology | 2024年 / 103卷
关键词
Tislelizumab; Monotherapy; Early-stage; Hodgkin Lymphoma;
D O I
暂无
中图分类号
学科分类号
摘要
The anti-PD-1 antibodies have been reported to show a striking effect in relapsed and refractory(R/R) classical Hodgkin lymphoma (cHL), however, there is still limited real-world data assessing the role of anti-PD-1 antibody monotherapy in early-stage cHL. In this retrospective analysis, we reported the effectiveness and safety of tislelizumab monotherapy in the first-line therapy of early-stage cHL. Twenty-three consecutive patients (10 males and 13 females) with previously untreated stage I A-II B cHL were included. At interim evaluation after 2 doses of tislelizumab monotherapy, 11 of 23 patients (47.8%) achieved complete response (CR). At the end of tislelizumab monotherapy (EOTM), objective response was observed in 22 of 23 patients (95.7%), with CR in 16 patients (69.6%). Among six patients with PR-EOTM, two patients underwent 4 cycles of ABVD chemotherapy and one patient underwent 4 cycles of tislelizumab plus AVD. One patient who developed progressive disease (PD) after 4 doses of tislelizumab subsequently underwent 4 cycles of ABVD chemotherapy. Except for four patients with CR-EOTM, consolidative radiotherapy was given to 19 patients. All patients obtained CR at the end of all treatments. With a median follow-up time of 21.3 months (range, 6.9–32.7 months), the estimated 2-year PFS rate and 2-year OS rate were 95.65% and 100%, respectively. Except for grade 3 lymphocyte count decreased, no other grade 3/4 TRAE was observed. In addition, no serious AE was reported. Our preliminary data observed that tislelizumab monotherapy was safe and highly effective in previously untreated early-stage cHL.
引用
收藏
页码:793 / 801
页数:8
相关论文
共 46 条
  • [21] Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis
    Momotow, Jesko
    Buehnen, Ina
    Trautmann-Grill, Karolin
    Kobbe, Guido
    Hahn, Dennis
    Schroers, Roland
    Heinrich, Bernhard
    Gaska, Tobias
    Forstbauer, Helmut
    Schmidt, Burkhard
    Boger, Regina
    Huettmann, Andreas
    Heil, Gerhard
    Kraemer, Doris M.
    Krueger, William
    Zeremski, Vanja
    Grobe, Norbert
    Jentsch-Ullrich, Kathleen
    Griesinger, Frank
    Fuchs, Michael
    von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    Broeckelmann, Paul J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 401 - 404
  • [22] Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma
    László Imre Pinczés
    Roxána Szabó
    Árpád Illés
    Dóra Földeák
    Klára Piukovics
    Árpád Szomor
    László Gopcsa
    Zsófia Miltényi
    Annals of Hematology, 2020, 99 : 2385 - 2392
  • [23] Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma
    Pinczes, Laszlo Imre
    Szabo, Roxana
    Illes, Arpad
    Foldeak, Dora
    Piukovics, Klara
    Szomor, Arpad
    Gopcsa, Laszlo
    Miltenyi, Zsofia
    ANNALS OF HEMATOLOGY, 2020, 99 (10) : 2385 - 2392
  • [24] Programmed Cell Death-Ligand 1 Expression and Clinical Outcomes Among Patients with Resected, Early-Stage Non-Small Cell Lung Cancer: A Real-World Study
    Cheema, Parneet K.
    Syed, Iqra
    Gwadry-Sridhar, Femida
    Rakibuz-Zaman, Muhammad
    Sachdeva, Robin
    Pencz, Alec
    Zhan, Luna
    Hueniken, Katrina
    Patel, Devalben
    Balaratnam, Karmugi
    Khan, Khaleeq
    Grant, Benjamin
    Sheffield, Brandon S.
    Locke, M. Elizabeth O.
    Moldaver, Daniel
    Shanahan, Mary Kate
    Liu, Geoffrey
    Kuruvilla, M. Sara
    CURRENT ONCOLOGY, 2024, 31 (11) : 6735 - 6748
  • [25] Real-World Biomarker Test Utilization and Subsequent Treatment in Patients with Early-Stage Non-small Cell Lung Cancer in the United States, 2011−2021
    Jessie T. Yan
    Yue Jin
    Ernest Lo
    Yilin Chen
    Amy E. Hanlon Newell
    Ying Kong
    Landon J. Inge
    Oncology and Therapy, 2023, 11 : 343 - 360
  • [26] Real-World Biomarker Test Utilization and Subsequent Treatment in Patients with Early-Stage Non-small Cell Lung Cancer in the United States, 2011-2021
    Yan, Jessie T. T.
    Jin, Yue
    Lo, Ernest
    Chen, Yilin
    Newell, Amy E. Hanlon E.
    Kong, Ying
    Inge, Landon J. J.
    ONCOLOGY AND THERAPY, 2023, 11 (03) : 343 - 360
  • [27] A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin's lymphoma
    Gaudio, Francesco
    Loseto, Giacomo
    Bozzoli, Valentina
    Scalzulli, Potito Rosario
    Mazzone, Anna Maria
    Tonialini, Lorenzo
    Fesce, Vincenza
    Quintana, Giovanni
    De Santis, Gaetano
    Masciopinto, Pierluigi
    Arcuti, Elena
    Clemente, Felice
    Scardino, Stefania
    Tarantini, Giuseppe
    Pastore, Domenico
    Melillo, Lorella
    Pavone, Vincenzo
    Maggi, Alessandro
    Carella, Angelo Michele
    Di Renzo, Nicola
    Guarini, Attilio
    Musto, Pellegrino
    ANNALS OF HEMATOLOGY, 2023, 102 (02) : 385 - 392
  • [28] A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma
    Francesco Gaudio
    Giacomo Loseto
    Valentina Bozzoli
    Potito Rosario Scalzulli
    Anna Maria Mazzone
    Lorenzo Tonialini
    Vincenza Fesce
    Giovanni Quintana
    Gaetano De Santis
    Pierluigi Masciopinto
    Elena Arcuti
    Felice Clemente
    Stefania Scardino
    Giuseppe Tarantini
    Domenico Pastore
    Lorella Melillo
    Vincenzo Pavone
    Alessandro Maggi
    Angelo Michele Carella
    Nicola Di Renzo
    Attilio Guarini
    Pellegrino Musto
    Annals of Hematology, 2023, 102 : 385 - 392
  • [29] Effectiveness and safety of adjuvant treatment of tislelizumab with or without chemotherapy in patients with high-risk upper tract urothelial carcinoma: a retrospective, real-world study
    Quan, Penghe
    Zhang, Longlong
    Yang, Bo
    Hou, Haozhong
    Wu, Ningli
    Fan, Xiaozheng
    Yu, Changjiang
    Zhu, He
    Feng, Tianxi
    Zhang, Yifan
    Qu, Kejun
    Yang, Xiaojian
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025, 27 (03): : 1221 - 1231
  • [30] National Survey of Real-World Australian Treatment Patterns for Patients With Very-Early-To Intermediate-Stage Hepatocellular Carcinoma
    Roberts, Stuart K.
    Majeed, Ammar
    Rasaratnam, Kiran
    Olynyk, John K.
    Shackel, Nicholas
    Wood, Marnie
    Strasser, Simone I.
    Wigg, Alan
    CANCER MEDICINE, 2025, 14 (05):